‘To switch or not to switch’: the missing piece in the puzzle of biosimilar literature?
Published on Jan 4, 2019in Annals of the Rheumatic Diseases14.299
· DOI :10.1136/annrheumdis-2018-214908
We read with great interest the paper from Glintborg and coauthors ‘To switch or not to switch’ reporting biosimilar etanercept switching in Denmark.1 In the Danish Biologic (DANBIO) cohort, patient treated with originator etanercept (Enbrel) were informed of a mandatory switch to SB4. However, the 25 mg pen or a powder-based preparation of original etanercept (OE) were still available. At 1 year after this decision, the authors reported that only 79% of patients had switched to SB4 and 21% remained treated with the originator biologic. In westernised countries, biologics therapies …